# Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

> **NCT01290536** · PHASE2 · COMPLETED · sponsor: **Nicholas Fidelman, MD** · enrollment: 42 (actual)

## Conditions studied

- Colorectal Neoplasms
- Neuroendocrine Tumors
- Cholangiocarcinoma
- Melanoma
- Breast Cancer

## Interventions

- **DEVICE:** Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)

## Key facts

- **NCT ID:** NCT01290536
- **Lead sponsor:** Nicholas Fidelman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290536, "Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01290536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*